Pneumococcal Disease

Single dose of 9-valent conjugate vaccine induces immunogenicity in children

Published in Vaccine Weekly, January 22nd, 2003

Researchers in South Africa have conducted a study to "determine the immunogenicity of a nonavalent pneumococcal conjugate vaccine after one dose, two doses, and three doses and its impact on the antibody response to coadministered antigens."

"A total of 500 infants from Soweto were immunized at 6, 10 and 14 weeks of age with either placebo (n=250) or 9-valent pneumococcal conjugate vaccine (n=250) containing serotypes 1, 4, 5, 6B, 9V, 14,18C, 19F, and 23F conjugated to CRM197 mutant diphtheria protein. Blood was taken for determination of serotype-specific IgG [immunoglobulin G] before the first dose and one month after each dose," wrote R.E. Huebner and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-01-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry